Everest Medicines

News

21 2021/01

Everest Medicines CEO Awarded the 13th Health China Top 10 Pharmaceutical Business Leaders Award
18 2021/01

Everest Medicines Announces Amended Agreement with Spero Therapeutics
06 2021/01

Everest Medicines Initiates Submission of New Drug Application in Singapore for Sacituzumab Govitecan-Hziy for the Treatment of Metastatic Triple-Negative Breast Cancer
06 2021/01

Everest Medicines Announces Approval of Clinical Trial Application by China National Medical Products Administration for Phase 3 Registration Trial of Sacituzumab Govitecan-Hziy for Metastatic Urothelial Cancer
22 2020/12

Everest Medicines Appoints Lan Kang to Board of Directors
09 2020/12

Everest Medicines Announces First Patient Dosed in Phase 3 Registration Asian Study of Trodelvy^™ (sacituzumab govitecan) for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
02 2020/12

Everest Medicines Announces The China Center for Drug Evaluation, National Medical Products Administration Recommends Breakthrough Therapy Designation for Nefecon for the Treatment of IgA Nephropathy
10 2020/11

Everest Medicines Announces that Licensing Partner Calliditas Therapeutics has Reported Positive Topline Results from Pivotal Phase 3 NefIgArd Trial
03 2020/11

Everest Medicines Announces First Patient Dosed in its Phase 2b Registration Clinical Trial of Trodelvy^™ (sacituzumab govitecan) for Metastatic Triple-Negative Breast Cancer in China
02 2020/11

Everest Medicines Announces Approval of Clinical Trial Application by China National Medical Products Administration for Phase 3 Registration Trial of Trodelvy^™ for Metastatic Breast Cancer in China
08 2020/10

Everest Medicines Announces the Offer Price and Allotment Results of the Global Offering
25 2020/09

Everest Medicines Announced Its Global Offering and Proposed Listing on the Stock Exchange of Hong Kong

Copyright Everest Medicines 2020 云顶药业（苏州）有限公司苏ICP备20038571号 | Terms of Use | Privacy Policy | Disclaimers

沪公网安备 31010602006477号